Company Overview

Update
Founded:
2007
Founders:
Kenneth E. Weg, Lynda Chin, Ronald A. DePinho, See All (4)
Headquarters:
Cambridge, MA
Funding:
$46.80M
Categories:
Biotechnology

Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.

Description

Update

Metamark Genetics, Inc is a life science company dedicated to the development of prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients, improved outcomes, and reduced healthcare costs.

Metamark was founded in November, 2007 to transform cancer diagnosis and treatment by developing pioneering diagnostic products based on its Prognosis Determinantsâ„¢ Platform. Prognosis Determinantsâ„¢ are functionally validated genetic elements at the core of cancer progression across many major cancer types. Based on pioneering research in melanoma by Dr. Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School, the Prognosis Determinantsâ„¢ were first discovered as functionally active drivers of metastasis that confer poor outcome. Prognosis Determinantsâ„¢ have been shown to be relevant to a broad spectrum of different tumors and can stratify patients according to their overall and metastasis-free survival.

Current Team (9)

Update

Board Members and Advisors (3)

Update

Funding Rounds (4) - $46.80M

Update

Investors (1)

Update
  • 82c9cc9b62bf59ba6324dfaa2dbb32c4

    Perseus

    Perseus, L.L.C. is a merchant bank and private equity fund management company headquartered in..

Offices/Locations (1)

Update
  • Office

    245 First Street

    Suite 150

    Cambridge, MA 02142

    USA